TD Cowen Maintains 2seventy Bio(TSVT.US) With Hold Rating
Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug
12 Health Care Stocks Moving In Thursday's After-Market Session
Leerink Partners Maintains 2seventy Bio(TSVT.US) With Buy Rating, Announces Target Price $15
Buy Rating Affirmed for 2seventy Bio Despite Trial Setback: Niche Market Strategy and Safety Profile Underpin Positive Outlook
Express News | 2Seventy Bio Inc : Leerink Partners Cuts Target Price to $15 From $25